Regeneron (REGN) Files Mixed Shelf Registration Statement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Regeneron Pharma (REGN) PT Lowered to $680 at Evercore ISI
November 4, 2021 4:11 PM EDTEvercore ISI analyst Dr. Josh Schimmer lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $680.00 (from $690.00) while maintaining a Outperform rating.... More
Regeneron beats quarterly sales on COVID-19 drug demand
November 4, 2021 6:42 AM EDT(Reuters) -Regeneron Pharmaceuticals Inc on Thursday reported higher-than-expected quarterly revenue on strong demand for its COVID-19 antibody cocktail during the Delta variant-led surge in infections in the United States.
U.S. sales of the cocktail, REGEN-COV, approved for emergency use in non-hospitalized COVID-19 patients, were $676.7 million in the third quarter, compared with analysts' estimates of $320.5... More
Regeneron (REGN) Tops Q3 EPS by $6.15
November 4, 2021 6:37 AM EDTRegeneron (NASDAQ: REGN) reported Q3 EPS of $15.37, $6.15 better than the analyst estimate of $9.22. Revenue for the quarter came in at $3.45 billion versus the consensus estimate of $2.76 billion.
For earnings history and earnings-related data on Regeneron (REGN) click here.
... More